A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351

References

• Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–13. doi:10.1038/s41586-020-2012-7.
   PubMed Web of Science ®Google Scholar
• Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, Slayton RB, Tong SX, Silk BJ, Armstrong GL, et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage-United States, December 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(3):95–99. doi:10.15585/mmwr.mm7003e2.
   PubMed Web of Science ®Google Scholar
• Pan HC, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Karim QA, Alejandria M, García CH, Kieny MP, Malekzadeh R, et al. Repurposed antiviral drugs for COVID-19 –interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511. doi:10.1056/NEJMoa2023184.
   Web of Science ®Google Scholar
• Saphire EO, Schendel SL, Gunn BM, Milligan JC, Alter G. Antibody-mediated protection against Ebola virus. Nat Immunol. 2018;19(11):1169–78. doi:10.1038/s41590-018-0233-9.
   PubMed Web of Science ®Google Scholar
• Mulangu S, Dodd LE, Davey RT, Mbaya OT, Proschan M, Mukadi D, Manzo ML, Nzolo D, Oloma AT, Ibanda A, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019;381(24):2293–303. doi:10.1056/NEJMoa1910993.
   PubMed Web of Science ®Google Scholar
• Yu F, Xiang R, Deng XQ, Wang LL, Yu ZG, Tian SJ, Liang RY, Li YB, Ying TL, Jiang SB. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduct Target Ther. 2020;5(1):212. doi:10.1038/s41392-020-00318-0.
   PubMed Web of Science ®Google Scholar
• Meulen JT, Brink ENVD, Poon LLM, Marissen WE, Leung CSW, Cox F, Cheung CY, Bakker AQ, Bogaards JA, Deventer EV, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3(7):e237. doi:10.1371/journal.pmed.0030237.
   Web of Science ®Google Scholar
• Corti D, Zhao JC, Pedotti M, Simonelli L, Agnihothram S, Fett C, Rodriguez BF, Foglierini M, Agatic G, Vanzetta F, et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci USA. 2015;112(33):10473–78. doi:10.1073/pnas.1510199112.
   PubMed Web of Science ®Google Scholar
• Yan RH, Zhang YY, Li YN, Xia L, Guo YY, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–48. doi:10.1126/science.abb2762.
   PubMed Web of Science ®Google Scholar
• Cao YL, Su B, Guo XH, Sun WJ, Deng YQ, Bao LL, Zhu QY, Zhang X, Zheng YH, Geng CY, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020;182(1):73–84. doi:10.1016/j.cell.2020.05.025.
   PubMed Web of Science ®Google Scholar
• Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010–14. doi:10.1126/science.abd0827.
   PubMed Web of Science ®Google Scholar
• Jones BE, Augsburger PLB, Corbett KS, Westendorf K, Davies J, Cujec TP, Wiethoff CM, Blackbourne JL, Heinz BA, Foster D, et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv. 2020. doi:10.1101/2020.09.30.318972.
   Google Scholar
• Shi R, Shan C, Duan XM, Chen ZH, Liu PP, Song JW, Song T, Bi XS, Han C, Wu LA, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–24. doi:10.1038/s41586-020-2381-y.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Naranjo LA, Kumar S, Gaiotto T, Mukundan H, Swanson B, Bradbury ARM. Using phage and yeast display to select hundreds of monoclonal antibodies: application to antigen 85, a tuberculosis biomarker. PLoS One. 2012;7(11):e49535. doi:10.1371/journal.pone.0049535.
   PubMed Web of Science ®Google Scholar
• Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol. 1994;12(1):433–55. doi:10.1146/annurev.iy.12.040194.002245.
   PubMedGoogle Scholar
• Li W, Chen C, Drelich A, Martinez DR, Gralinski LE, Sun Z, Schäfer A, Kulkarni SS, Liu XL, Leist SR, et al. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. Proc Natl Acad Sci USA. 2020;117(47):29832–38. doi:10.1073/pnas.2010197117.
   Google Scholar
• Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 1997;15(6):553–57. doi:10.1038/nbt0697-553.
   PubMed Web of Science ®Google Scholar
• Jarasch A, Koll H, Regula JT, Bader M, Papadimitriou A, Kettenberger H. Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci. 2015;104(6):1885–98. doi:10.1002/jps.24430.
   PubMed Web of Science ®Google Scholar
• Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, Sette A, Peters B, Nielsen M. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 2018;154(3):394–406. doi:10.1111/imm.12889.
   PubMed Web of Science ®Google Scholar
• King C, Garza EN, Mazor R, Linehan JL, Pastan I, Pepper M, Removing BD. T-cell epitopes with computational protein design. Proc Natl Acad Sci USA. 2014;111(23):8577–82. doi:10.1073/pnas.1321126111.
   PubMed Web of Science ®Google Scholar
• Hristodorov D, Fischer R, Joerissen H, Tiemann BM, Apeler H, Linden L. Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies. Mol Biotechnol. 2013;53(3):326–35. doi:10.1007/s12033-012-9531-x.
   PubMed Web of Science ®Google Scholar
• Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov. 2012;11(4):311–31. doi:10.1038/nrd2909.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328(5979):745–48. doi:10.1126/science.1185181.
   PubMed Web of Science ®Google Scholar
• Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, Balmaseda A, Harris E. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929–32. doi:10.1126/science.aan6836.
   PubMed Web of Science ®Google Scholar
• Kam YW, Kien F, Roberts A, Cheung YC, Lamirande EW, Vogel L, Chu SL, Tse J, Guarner J, Zaki SR, et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro. Vaccine. 2007;25(4):729–40. doi:10.1016/j.vaccine.2006.08.011.
   PubMed Web of Science ®Google Scholar
• Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, Dutry I, Callendret B, Escriou N, Altmeyer R, et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway. J Virol. 2011;85(20):10582–97. doi:10.1128/JVI.00671-11.
   PubMed Web of Science ®Google Scholar
• Tortorici MA, Beltramello M, Lempp FA, Pinto D, Dang HV, Rosen LE, Callum MM, Bowen J, Minola A, Jaconi S, et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science. 2020;370(6519):950–57. doi:10.1126/science.abe3354.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Corti D, Virgin HW, Ravetch JV. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature. 2020;588(7838):485–90. doi:10.1038/s41586-020-2838-z.
   Google Scholar
• Li QQ, Wu JJ, Nie JH, Zhang L, Hao H, Liu S, Zhao CY, Zhang Q, Liu H, Nie LL, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284–1294.e9. doi:10.1016/j.cell.2020.07.012.
   PubMedGoogle Scholar
• Ou J, Zhou ZH, Dai RX, Zhang J, Lan WD, Zhao S, Wu JG, Seto D, Cui LL, Zhang G, et al. V367F mutation in SARS-CoV-2 spike RBD emerging during the early transmission phase enhances viral infectivity through increased human ACE2 receptor binding affinity. bioRxiv. 2020. doi:10.1101/2020.03.15.991844.
   Google Scholar
• Yurkovetskiy L, Wang X, Pascal KE, Tomkins-Tinch C, Nyalile TP, Wang YT, Baum A, Diehl WE, Dauphin A, Carbone C, et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell. 2020;183(3):739–751.e8. doi:10.1016/j.cell.2020.09.032.
   Google Scholar
• Plante JA, Liu Y, Liu JY, Xia HJ, Johnson BA, Lokugamage KG, Zhang XW, Muruato AE, Zou J, Fontes-Garfias CR, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592(7852):116–21. doi:10.1038/s41586-020-2895-3.
   PubMed Web of Science ®Google Scholar
• Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812–827.e19. doi:10.1016/j.cell.2020.06.043.
   PubMed Web of Science ®Google Scholar
• Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, Connor T, Peacock T, Robertson DL, Volz E, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. 2020. [accessed Dec 19 2020]. https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563.
   Google Scholar
• Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San EJ, Msomi N, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020. doi:10.1101/2020.12.21.20248640.
   Google Scholar
• Wang PF, Liu LH, Iketani S, Luo Y, Guo YC, Wang M, Yu J, Zhang BS, Kwong PD, Graham BS, et al. Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv. 2021. doi:10.1101/2021.01.25.428137..
   Google Scholar
• Wang S, Peng Y, Wang RJ, Jiao SS, Wang M, Huang WJ, Shan C, Wen J, Li ZP, Gu CY, et al. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nat Commun. 2020;11(1):5752. doi:10.1038/s41467-020-19568-1.
   PubMed Web of Science ®Google Scholar
• Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014–18. doi:10.1126/science.abd0831.
   PubMed Web of Science ®Google Scholar
• Benatuil L, Perez JM, Belk J, Hsieh CM. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng Des Sel. 2010;23(4):155–59. doi:10.1093/protein/gzq002.
   PubMed Web of Science ®Google Scholar
• Lefranc MP. IMGT, the international ImMunoGeneTics information system. Cold Spring Harb Protoc. 2011;2011(6):595–603. doi:10.1101/pdb.top115.
   Google Scholar